Follow The Filings

IKT Inhibikase Therapeutics

Inhibikase Therapeutics earnings company data as of 4:48 AM ET 10/23

Limited consensus data for this ticker (thin coverage or data-plan limits). Dates may be company-announced rather than sell-side consensus. Calendar and recent prints remain the primary lens when available.

Scheduled

1 period, newest first, nothing reported yet. Each row shows EPS above revenue.

Period Date Metric Estimate Actual Result
FY2026 Q3 13 Nov EPS — — —
Rev — — —

Insider trades

Open-market buys and sales by IKT's executives, directors and 10% owners in the last 12 months, from their Form 4s

All IKT insider trades
  • $3M bought by 1 insider
  • None no sales outside a trading plan
  • None no planned (10b5-1) sales
  1. Sands Capital Life Sciences Pulse Fund II, L.P. 10% owner, +2 joint filers
    Buy
    $3M 2,068,965 shares at $1.45 +19% to stake
    Traded Nov 21, 2025 Filed Nov 24, 2025
    ↗

Also filed in the last 12 months, not counted as buying or selling: 3 sales back to the company, 1 other transaction, and 1 option exercise.

SEC filings

Recent issuer filings from EDGAR, 25 shown.

Filed Form Detail Links
8-K 5.02,7.01,9.01 Filing Doc
8-K 7.01,9.01 Filing Doc
8-K 4.01,9.01 Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 3.02,9.01 Filing Doc
SCHEDULE 13G — Filing Doc
8-K 7.01,9.01 Filing Doc
SCHEDULE 13G — Filing Doc
8-K 8.01,9.01 Filing Doc
8-K 5.02,5.03,5.07,9.01 Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc
DEF 14A Filing Doc
DEFA14A Filing Doc
8-K 7.01,9.01 Filing Doc
8-K 2.02,9.01 Filing Doc

Source: SEC EDGAR submissions, updated 2 days ago. All on EDGAR

Estimates are consensus figures; SEC filings remain the official record. Not investment advice.